<DOC>
	<DOCNO>NCT02396199</DOCNO>
	<brief_summary>The Zenith® p-Branch® Pivotal Study clinical trial approve FDA study safety effectiveness Zenith® p-Branch® endovascular graft combination Atrium iCAST™ cover stent treatment abdominal aortic aneurysm .</brief_summary>
	<brief_title>Zenith® p-Branch® Endovascular Graft Pivotal Study</brief_title>
	<detailed_description />
	<mesh_term>Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm , Abdominal</mesh_term>
	<criteria>Pararenal juxtarenal AAA ≥5.0 cm diameter 2 time normal aortic diameter Pararenal juxtarenal AAA history growth ≥0.5 cm/year Saccular aneurysm aortic diameter great 1.5 time normal aortic diameter deem risk rupture base upon physician interpretation Age &lt; 18 year Life expectancy &lt; 2 year Pregnant , breastfeeding , plan become pregnant within 60 month Inability refusal give informed consent patient legally authorize representative Unwilling unable comply followup schedule Simultaneously participate another investigative device drug study . ( The patient must complete primary endpoint previous study least 30 day prior enrollment study . ) Additional medical restriction specify Clinical Investigation Plan Additional anatomical restriction specify Clinical Investigation Plan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Abdominal aortic aneurysm</keyword>
	<keyword>Endovascular</keyword>
	<keyword>Juxtarenal</keyword>
	<keyword>Pararenal</keyword>
	<keyword>Fenestrated</keyword>
</DOC>